Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-Current Deffered Revenue: 2019-2021

Historic Non-Current Deffered Revenue for Fulcrum Therapeutics (FULC) over the last 3 years, with Dec 2021 value amounting to $1.7 million.

  • Fulcrum Therapeutics' Non-Current Deffered Revenue fell 43.45% to $1.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $1.7 million, marking a year-over-year decrease of 43.45%. This contributed to the annual value of $1.7 million for FY2021, which is 43.45% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $1.7 million for Q4 2021, which was up 2.31% from $1.6 million recorded in Q3 2021.
  • In the past 5 years, Fulcrum Therapeutics' Non-Current Deffered Revenue registered a high of $6.0 million during Q4 2019, and its lowest value of $1.5 million during Q3 2019.
  • Over the past 3 years, Fulcrum Therapeutics' median Non-Current Deffered Revenue value was $2.1 million (recorded in 2019), while the average stood at $3.1 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Non-Current Deffered Revenue surged by 290.64% in 2020, and later tumbled by 72.47% in 2021.
  • Over the past 3 years, Fulcrum Therapeutics' Non-Current Deffered Revenue (Quarterly) stood at $6.0 million in 2019, then tumbled by 50.57% to $3.0 million in 2020, then plummeted by 43.45% to $1.7 million in 2021.
  • Its last three reported values are $1.7 million in Q4 2021, $1.6 million for Q3 2021, and $1.7 million during Q2 2021.